Proceedings · Session S-441 · filed November 19, 2026
Translational ScienceSession paper
Mirvetuximab resensitizes colorectal tumors to anti-PD-1 in mice
An approved FOLR1 antibody-drug conjugate restored anti-PD-1 activity in resistant colorectal tumors in mice, with proteomics linking FOLR1 to STAT1 regulation and MHC-I loss.
By Sophie Lindqvist3 min read690 words
Summary
- Only 15% of colorectal cancer patients experience substantial benefit from treatments such as anti-PD-1.
- Colorectal cancer is the third most common cancer worldwide.
- FOLR1 stabilized AARS1, leading to STAT1 lactylation at K193 and dephosphorylation at Y701.
- Mirvetuximab soravtansine restored antitumor immunity and resensitized colorectal tumors to anti-PD-1 in mice.
- The report provides no mouse sample sizes, dosing details, effect sizes, or funding source.

Only 15% of colorectal cancer patients experience substantial benefit from treatments such as anti-PD-1, according to the study’s background, which tested an approved FOLR1-targeted antibody-drug conjugate to restore checkpoint-blockade activity in resistant mouse tumors.
Colorectal cancer ranks as the third most common cancer worldwide. The study appeared in Science Translational Medicine as "Targeting cancer immune evasion with anti-FOLR1 antibody-drug conjugate potentiates anti-PD-1 efficacy in colorectal cancer." Its central result is preclinical: mirvetuximab soravtansine resensitized colorectal tumors to anti-PD-1 blockade in mice.
Why do some colorectal tumors resist checkpoint blockade?
Tumor properties can limit immunotherapy, including defects in MHC-I expression. The report links loss of MHC-I antigen presentation to immune evasion and resistance to immune checkpoint blockade in colorectal cancer. Previous work also associated folate receptor α, or FOLR1, with more aggressive progression and poorer prognosis across several solid-tumor types.
The researchers ran fluorescence-activated cell sorting-based CRISPR activation screens with a druggable-genome library. FOLR1 emerged as a top negative regulator of immune-checkpoint response. "High expression of FOLR1 predicted a poor ICB response, enhanced cancer stemness, and unfavorable patient outcomes," the team reported.
That association defines a candidate biomarker and intervention target, but it does not show that FOLR1 alone causes resistance in every patient. The supplied report gives no patient-group size, response definition, assay method for the association, or treatment-effect estimate. For portfolio screening, those omissions limit any calculation of the eligible population or the budget required for a combination study.
What mechanism linked FOLR1 to immune escape?
Proteomic analyses showed that FOLR1 stabilized AARS1, an alanyl-tRNA synthetase 1 described in the paper as a lactyltransferase. The chain identified in the study proceeds through two measured molecular events:
- AARS1 lactylated signal transducer and activator of transcription 1, or STAT1, at lysine 193, also written K193.
- That modification promoted STAT1 interaction with TCPTP, or T cell protein-tyrosine phosphatase, and induced STAT1 dephosphorylation at tyrosine 701.
The source does not report effect sizes for either modification or the assays used to establish causality. Its functional experiments nevertheless connect the pathway with antigen presentation and T-cell recognition. In vitro, FOLR1 indirectly reduced STAT1 signaling activity and dampened MHC-I activity. That supported tumor-cell adaptability and prevented CD8+ T cells from engaging the cancer cells, according to the study.
What changed when researchers blocked FOLR1?
The team tested mirvetuximab soravtansine, an approved antibody-drug conjugate that inhibits FOLR1. In mice, the compound restored antitumor immunity and resensitized colorectal tumors to anti-PD-1 blockade. These results support adding FOLR1-directed treatment to an existing checkpoint regimen as a way to overcome a documented resistance mechanism, at least in the tested models.
The treatment result remains separate from the paper’s clinical projection. The authors state that integrating FOLR1-based drugs into existing regimens could improve outcomes in patients with treatment-resistant tumors. The study did not report patient efficacy data for mirvetuximab soravtansine in colorectal cancer. The source also does not identify the compound’s approval indication, and approval alone does not establish efficacy in this combination or disease setting.
"Our findings support anti-FOLR1 [antibody-drug conjugate] as a clinically actionable approach to overcome immune evasion and unlock immunotherapy efficacy in [colorectal cancer]," the authors wrote.
What should sponsors verify before acting?
The supplied report does not identify who funded the work, list author affiliations, or provide conflict disclosures. It also gives no mouse-model details, sample sizes, doses, endpoints, or statistical thresholds. It does not identify the human biomarker cohort, its size, or the effect estimate linking FOLR1 to anti-PD-1 response. An R&D team should obtain those data from the full paper and confirm reproducibility before committing to combination development.
The immediate laboratory question is whether FOLR1 expression can stratify resistant tumors and whether blocking the receptor produces a durable anti-PD-1 response beyond the reported mouse experiment. For R&D leaders, the next decision is whether human FOLR1-stratified data justify a controlled combination trial; mouse resensitization alone does not settle that case.
via science.org (Original)
Filed under
- colorectal-cancer
- folr1
- mirvetuximab-soravtansine
- anti-pd-1-immunotherapy
- antibody-drug-conjugates
More from Sophie Lindqvist
Show full bio
Correspondent covering money, funding and market shifts around research and development at Hypothesis Wire.
246 articles
References
- Agenus Brings BOT/BAL Survival Data to SITC 2026
- DUSP4 protein keeps CAR-T cells killing colorectal tumours, NUS study finds
- Cancer Cell publishes sac-TMT plus osimertinib translational data
- Agenus Brings BOT+BAL Survival Data and agenT-797 Findings to SITC 2026
- Merck-Moderna melanoma vaccine cuts recurrence risk 42% at ESMO 2026